No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.

Yalcinkaya, Ahmet; Cavalli, Marco; Cederholm, Axel; Aranda-Guillén, Maribel; Behere, Anish; Mildner, Hedvig; Lakshmikanth, Tadepally; Gonzalez, Laura; Mugabo, Constantin Habimana; Johnsson, Anette; Ekwall, Olov; Kämpe, Olle; Bensing, Sophie; Brodin, Petter; Hallberg, Pär; Wadelius, Mia; Landegren, Nils

Yalcinkaya, Ahmet; Cavalli, Marco; Cederholm, Axel; Aranda-Guillén, Maribel; Behere, Anish; Mildner, Hedvig; Lakshmikanth, Tadepally; Gonzalez, Laura; Mugabo, Constantin Habimana; Johnsson, Anette; Ekwall, Olov; Kämpe, Olle; Bensing, Sophie; Brodin, Petter; Hallberg, Pär; Wadelius, Mia; Landegren, Nils.

Afiliação

Yalcinkaya A; Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden. ahmet.yalcinkaya@imbim.uu.se.
Cavalli M; Department of Medical Biochemistry, Hacettepe University Hospital, Ankara, Turkey. ahmet.yalcinkaya@imbim.uu.se.
Cederholm A; Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Aranda-Guillén M; Department of Medical Sciences, Clinical Pharmacogenomics, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Behere A; Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Mildner H; Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.
Lakshmikanth T; Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Gonzalez L; Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Mugabo CH; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Johnsson A; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Ekwall O; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Kämpe O; Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Bensing S; Department of Pediatrics, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Brodin P; Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Hallberg P; Center for Molecular Medicine, Department of Medicine (Solna), Karolinska Institutet, Stockholm, Sweden.
Wadelius M; Department of Clinical Science, University of Bergen, Bergen, Norway.
Landegren N; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.

NPJ Vaccines ; 9(1): 42, 2024 Feb 22.

Article em En | MEDLINE | ID: mdl-38388530

ABSTRACT

ABSTRACT

Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: NPJ Vaccines Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suécia

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google